Founded in April 2019, RNACure BioPharma is an innovative drug company focused on mRNA technology innovation and product development. We have built a full-chain mRNA drug technology platform spanning target discovery, sequence design, delivery systems, manufacturing processes, quality control, supply chain, and industrialization. The core team comprises leading scientists from Harvard, Yale, the Karolinska Institute, Peking University, PUMC, and other renowned institutions, with more than a decade of mRNA research experience. We are committed to breakthroughs in foundational mRNA technologies, building an integrated R&D-to-manufacturing platform, advancing an end-to-end mRNA industry ecosystem, accelerating clinical translation of mRNA medical products, and driving development across infectious disease vaccines, cancer vaccines, protein replacement therapy, gene-editing therapy, and veterinary vaccines, aiming to become a global leader in mRNA drug R&D.

In Chinese mythology, the blue magpie is a sacred bird. Legend says the Queen Mother of the West had three blue birds: one was sent as a messenger to the Han emperor, and two accompanied her in service. She is a deity of auspiciousness and longevity. As a messenger, the blue magpie's long tail symbolizes health and longevity. RNACure seeks to unlock more functions of mRNA to enable easier, safer, and more economical mRNA therapies. We have built a simple, one-step mRNA drug development platform spanning mRNA synthesis, early target discovery, and rapid product line expansion, focusing on mRNA vaccines and mRNA-based therapies for severe diseases.